Analysis of the clinical therapeutic effect of regorafenib (Belvango) on patients with lung cancer

Regorafenib is a multi-target oral small molecule kinase inhibitor initially used for the treatment of colorectal cancer, gastrointestinal stromal tumors and hepatocellular carcinoma. In recent years, with in-depth research on its anti-tumor mechanism, the application of regorafenib in patients with lung cancer, especially non-small cell lung cancer (NSCLC), has gradually attracted clinical attention. Its mechanism of action is mainly through inhibiting angiogenesis-related pathways (such as VEGFR), tumor cell proliferation-related pathways (such as KIT, RET, etc.) and microenvironmental signals, thereby showing potential therapeutic value in the progression of lung cancer.

In clinical practice, some patients with advanced non-small cell lung cancer still develop drug resistance or disease progression after receiving standard treatments (such as targeted therapy or immunotherapy). At this time, regorafenib, as a multi-target drug, provides a new treatment option for these patients. Clinical data shows that regorafenib combined with immune checkpoint inhibitors or chemotherapy regimens has demonstrated a certain objective response rate and disease control rate in some lung cancer patients, can delay disease progression, and improve the progression-free survival of patients to a certain extent (PFS). This makes regorafenib an important addition to the exploration of later-line treatments.

In terms of safety, the tolerability of regorafenib in patients with lung cancer is generally controllable. Common adverse reactions include hand-foot skin reaction, hypertension, fatigue, decreased appetite, and gastrointestinal-related discomfort. Most of these side effects can be alleviated through dose adjustment and symptomatic and supportive treatment. It should be noted that long-term use of regorafenib may cause abnormalities in liver function indicators. Therefore, it is recommended that patients conduct regular liver function and blood pressure monitoring during treatment to intervene promptly when adverse reactions occur to ensure the continuity and safety of treatment.

Overall, the application of regorafenib in the field of lung cancer is still in the exploratory and clinical research stages, but existing data show that it has certain efficacy advantages in patients with advanced, drug-resistant non-small cell lung cancer, especially in combination therapy. With the release of more clinical trial results, regorafenib is expected to further clarify its positioning in the treatment of lung cancer and bring new hope to some patient groups who lack effective treatments.

Reference link:https://www.drugs.com